AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.

10x Science, a startup founded in December 2025, has raised a $4.8 million seed round to tackle a growing bottleneck in AI-driven drug discovery: characterizing the flood of molecular candidates that AI models generate. Founded by biochemists from Nobel laureate Carolyn Bertozzi's Stanford lab and an AI expert, the company combines deterministic chemistry/biology algorithms with AI agents to interpret complex mass spectrometry data. Their platform automates analysis that previously required significant expertise and time, making it accessible to pharma companies and academic researchers. Early users report the tool accurately explains its conclusions, autonomously finds relevant data, and adapts to different molecule types. The company plans to use the seed funding to hire engineers and expand its customer base.